Literature DB >> 26272943

Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease.

Adelin Gustot1, José Ignacio Gallea2, Rabia Sarroukh3, María Soledad Celej2, Jean-Marie Ruysschaert3, Vincent Raussens3.   

Abstract

Parkinson's disease (PD) is an age-related movement disorder characterized by a progressive degeneration of dopaminergic neurons in the midbrain. Although the presence of amyloid deposits of α-synuclein (α-syn) is the main pathological feature, PD brains also present a severe permanent inflammation, which largely contributes to neuropathology. Although α-syn has recently been implicated in this process, the molecular mechanisms underlying neuroinflammation remain unknown. In the present study, we investigated the ability of different α-syn aggregates to trigger inflammatory responses. We showed that α-syn induced inflammation through activation of Toll-like receptor 2 (TLR2) and the nucleotide oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome only when folded as amyloid fibrils. Oligomeric species, thought to be the primary species responsible for the disease, were surprisingly unable to trigger the same cascades. As neuroinflammation is a key player in PD pathology, these results put fibrils back to the fore and rekindles discussions about the primary toxic species contributing to the disease. Our data also suggest that the inflammatory properties of α-syn fibrils are linked to their intrinsic structure, most probably to their cross-β structure. Since fibrils of other amyloids induce similar immunological responses, we propose that the canonical fibril-specific cross-β structure represents a new generic motif recognized by the innate immune system.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  amyloid fibril; cross-β structure; nucleotide oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome; oligomer; structure-inflammatory properties relationship; α-synuclein

Mesh:

Substances:

Year:  2015        PMID: 26272943     DOI: 10.1042/BJ20150617

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  53 in total

1.  Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.

Authors:  Souvarish Sarkar; Hai M Nguyen; Emir Malovic; Jie Luo; Monica Langley; Bharathi N Palanisamy; Neeraj Singh; Sireesha Manne; Matthew Neal; Michelle Gabrielle; Ahmed Abdalla; Poojya Anantharam; Dharmin Rokad; Nikhil Panicker; Vikrant Singh; Muhammet Ay; Adhithiya Charli; Dilshan Harischandra; Lee-Way Jin; Huajun Jin; Srikant Rangaraju; Vellareddy Anantharam; Heike Wulff; Anumantha G Kanthasamy
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

2.  The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1β transcription and activate the NLRP3 inflammasome.

Authors:  Raquel Domingo-Fernández; Rebecca C Coll; Jay Kearney; Samuel Breit; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2017-06-02       Impact factor: 5.157

3.  Telmisartan Inhibits the NLRP3 Inflammasome by Activating the PI3K Pathway in Neural Stem Cells Injured by Oxygen-Glucose Deprivation.

Authors:  Hyuk Sung Kwon; Jungsoon Ha; Ji Young Kim; Hyun-Hee Park; Eun-Hye Lee; Hojin Choi; Kyu-Yong Lee; Young Joo Lee; Seong-Ho Koh
Journal:  Mol Neurobiol       Date:  2021-01-06       Impact factor: 5.590

Review 4.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

Review 5.  Inflammasomes link vascular disease with neuroinflammation and brain disorders.

Authors:  Nikolett Lénárt; David Brough; Ádám Dénes
Journal:  J Cereb Blood Flow Metab       Date:  2016-08-02       Impact factor: 6.200

6.  NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease.

Authors:  Hayate Javed; Ramasamy Thangavel; Govindhasamy Pushpavathi Selvakumar; Iuliia Dubova; Noah Schwartz; Mohammad Ejaz Ahmed; Smita Zaheer; Duraisamy Kempuraj; Shankar Iyer; Asgar Zaheer; Mohammad Moshahid Khan
Journal:  Int Immunopharmacol       Date:  2020-04-04       Impact factor: 4.932

7.  The Ketone Body β-Hydroxybutyrate Does Not Inhibit Synuclein Mediated Inflammasome Activation in Microglia.

Authors:  Vandana Deora; Eduardo A Albornoz; Kevin Zhu; Trent M Woodruff; Richard Gordon
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-23       Impact factor: 4.147

8.  Synchrotron Infrared and Deep UV Fluorescent Microspectroscopy Study of PB1-F2 β-Aggregated Structures in Influenza A Virus-infected Cells.

Authors:  Christophe Chevalier; Ronan Le Goffic; Frédéric Jamme; Olivier Leymarie; Matthieu Réfrégiers; Bernard Delmas
Journal:  J Biol Chem       Date:  2016-02-19       Impact factor: 5.157

9.  α-Synuclein Amyloid Fibrils with Two Entwined, Asymmetrically Associated Protofibrils.

Authors:  Altaira D Dearborn; Joseph S Wall; Naiqian Cheng; J Bernard Heymann; Andrey V Kajava; Jobin Varkey; Ralf Langen; Alasdair C Steven
Journal:  J Biol Chem       Date:  2015-12-07       Impact factor: 5.157

10.  α-Synuclein activates innate immunity but suppresses interferon-γ expression in murine astrocytes.

Authors:  Jintang Wang; Zheng Chen; Jeremy D Walston; Peisong Gao; Maolong Gao; Sean X Leng
Journal:  Eur J Neurosci       Date:  2018-05-19       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.